ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Cardiology · J Am Heart Assoc · 2026-07-08

Post hoc analysis of 1040 patients with AF and stable coronary disease: edoxaban alone vs edoxaban plus an antiplatelet had fewer total net adverse clinical events at 12 months (9.4 vs 19.8 per 100 person-years; IRR 0.47), mostly bleeding; ischaemic events and death similar.

Secondary analysisn = 1,040
Kim et al. Total Clinical Event Burden With Edoxaban Monotherapy Versus Dual Antithrombotic Therapy in Atrial Fibrillation and Stable Coronary Artery Disease: Insights From the EPIC-CAD Trial
Cardiology · J Am Heart Assoc · 2026-05-14

Post hoc analysis of ELDERCARE-AF in 427 very old Japanese patients with AF on edoxaban 15 mg: higher trough edoxaban levels were associated with more major bleeding (0.8% to 4.7%/year by quartile), and PT >13 s with more bleeding (4.61% vs 0.98%/year).

Secondary analysisn = 427
Okumura et al. Association of Edoxaban Pharmacokinetics With Bleeding in Older Patients With Atrial Fibrillation Treated With Low-Dose Edoxaban: A Post Hoc Analysis of a Randomized Controlled Trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.